makeitgoaway
09-11-2006, 07:32 AM
Wyeth/Amgen's Enbrel to Achieve Blockbuster Status by 2010 for the Treatment of Psoriasis
Extent of Market Penetration by Premium-Priced Biologics Will Hinge on
Scrutiny of Third-Party Payers, According to a New Report from Decision
Resources
WALTHAM, Mass., Sept. 11 /PRNewswire/ -- Decision Resources, Inc., one
of the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that Wyeth/Amgen's Enbrel (etanercept) will
achieve blockbuster status for the treatment of psoriasis by 2010. Because
physicians recognize Enbrel as the biologic therapy that provides the best
balance of safety and efficacy, it will continue to lead sales among
biologics approved for psoriasis through 2015, despite competition from
Abbott/Eisai's Humira (adalimumab) after its expected launch.
The new Pharmacor report entitled Psoriasis finds that despite slow
growth in psoriasis prevalence, modest diagnosis rates, and a small
drug-treated population, the market to treat the disease will more than
double from $1.5 billion in 2005 to over $3.5 billion by 2015 in the United
States, France, Germany, Italy, Spain, the United Kingdom, and Japan. The
increasing demand for biologics and the introduction of new agents for
moderate-to-severe psoriasis will drive this growth. The report also finds
that, although dermatologists increasingly endorse the use of biologics for
psoriasis, the extent to which biologics will penetrate the market will
depend on third-party payers.
"The most important constraint on the uptake of biologics in the
psoriasis market will come from third-party payers as they scrutinize each
biologic agent's cost-effectiveness," said Joanna Kim, analyst at Decision
Resources, Inc. "At present, the reimbursement environment for psoriasis in
the United States is more permissive than in Europe. However, this scenario
will likely change as payers universally tighten their control over the use
of biologics and weigh the relatively low disease burden of psoriasis
against the more urgent medical needs that biologics address for conditions
such as rheumatoid arthritis."
About Psoriasis
Psoriasis is a lifelong inflammatory skin condition that affects 1 to
2% of the populations under study. Psoriasis is thought to arise from a
combination of factors, including genetics, environmental triggers,
associated diseases (particularly infection), and immunological status.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master
their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
SOURCE Decision Resources, Inc.
Extent of Market Penetration by Premium-Priced Biologics Will Hinge on
Scrutiny of Third-Party Payers, According to a New Report from Decision
Resources
WALTHAM, Mass., Sept. 11 /PRNewswire/ -- Decision Resources, Inc., one
of the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that Wyeth/Amgen's Enbrel (etanercept) will
achieve blockbuster status for the treatment of psoriasis by 2010. Because
physicians recognize Enbrel as the biologic therapy that provides the best
balance of safety and efficacy, it will continue to lead sales among
biologics approved for psoriasis through 2015, despite competition from
Abbott/Eisai's Humira (adalimumab) after its expected launch.
The new Pharmacor report entitled Psoriasis finds that despite slow
growth in psoriasis prevalence, modest diagnosis rates, and a small
drug-treated population, the market to treat the disease will more than
double from $1.5 billion in 2005 to over $3.5 billion by 2015 in the United
States, France, Germany, Italy, Spain, the United Kingdom, and Japan. The
increasing demand for biologics and the introduction of new agents for
moderate-to-severe psoriasis will drive this growth. The report also finds
that, although dermatologists increasingly endorse the use of biologics for
psoriasis, the extent to which biologics will penetrate the market will
depend on third-party payers.
"The most important constraint on the uptake of biologics in the
psoriasis market will come from third-party payers as they scrutinize each
biologic agent's cost-effectiveness," said Joanna Kim, analyst at Decision
Resources, Inc. "At present, the reimbursement environment for psoriasis in
the United States is more permissive than in Europe. However, this scenario
will likely change as payers universally tighten their control over the use
of biologics and weigh the relatively low disease burden of psoriasis
against the more urgent medical needs that biologics address for conditions
such as rheumatoid arthritis."
About Psoriasis
Psoriasis is a lifelong inflammatory skin condition that affects 1 to
2% of the populations under study. Psoriasis is thought to arise from a
combination of factors, including genetics, environmental triggers,
associated diseases (particularly infection), and immunological status.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master
their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
SOURCE Decision Resources, Inc.